Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Understanding the JAK2 mutation
Understanding the JAK2 Mutation
August 30, 2016
hearing loss in PV
Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
September 21, 2016

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

ropeginterferon

Key points

  • The novel IFNα-2b AOP2014 administered once every two weeks (or once a month) has low toxicity and induces high and sustained response rates in PV patients.

  • AOP2014 induces significant partial and complete molecular response rates, as reflected by reduction of JAK2 allelic burden.

  • Click here for the complete article

Dr Richard Silver On Ropeginterferon Alfa-2b (January 2016)


PV Reporter interviewed Dr Heinz Gisslinger at ASH 2014

 

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Malcare WordPress Security